I estimate that if they hit production and cost targets as per equity raising preso, absent material working capital movements, they should be roughly cash breakeven in the Sep Q and slightly positive in the Dec Q.
~$5m extra could provide significant buffer and avert a further CR.
But agree no sense in following rights if you can buy cheaper in the market, which you can currently.
